Patents by Inventor Dong Fang

Dong Fang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CANCER TARGETS AND USES THEREOF
    Publication number: 20130078253
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Application
    Filed: March 30, 2012
    Publication date: March 28, 2013
    Applicant: CELERA CORPORATION
    Inventors: Dong FANG, Paul MOORE, Steve RUBEN, Sudeepta AGGARWAL
  • AGONISTS OF GPR131 AND USES THEREOF
    Publication number: 20130059856
    Abstract: Chemical compounds which act as agonists of, or otherwise modulate the activity of, GPR131 are disclosed. Related compositions, formulations and methods of use are also described.
    Type: Application
    Filed: June 13, 2012
    Publication date: March 7, 2013
    Inventors: Aaron Robert Novack, Dong-Fang Shi, Jingyuan Ma, Imad Nashashibi, Phuongly Pham, Jiangao Song, David W. G. Wone, Xueyan Wang, Jeffrey D. Johnson, Brian Edward Lavan, Charles A. McWherter, Xin Chen
  • BICYCLIC AGONISTS OF GPR131 AND USES THEREOF
    Publication number: 20130059845
    Abstract: The present disclosure relates to compounds that act as agonists of, or otherwise modulate the activity of, GPR131 and to their use in the treatment of various diseases. In particular embodiments, the structure of the compounds is given by Formula I: wherein the variables are as described herein. Related compositions, formulations and methods for the preparation of compounds of formula I are also described.
    Type: Application
    Filed: August 24, 2012
    Publication date: March 7, 2013
    Inventors: Jiangao SONG, Phuongly Pham, Jingyuan Ma, Aaron Robert Novack, Imad Nashashibi, David W. G. Wone, Dong-Fang Shi, Xin Chen
  • N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS
    Publication number: 20120322804
    Abstract: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control.
    Type: Application
    Filed: May 3, 2012
    Publication date: December 20, 2012
    Inventors: Jingyuan Ma, Christopher J. Rabbat, Jiangao Song, Xin Chen, Imad Nashashibi, Zuchun Zhao, Aaron Novack, Dong Fang Shi, Peng Cheng, Yan Zhu, Alison Murphy
  • GPR120 receptor agonists and uses thereof
    Patent number: 8309600
    Abstract: GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: November 13, 2012
    Assignee: Metabolex Inc.
    Inventors: Dong Fang Shi, Jiangao Song, Jingyuan Ma, Aaron Novack, Phuongly Pham, Imad Fayek Nashashibi, Christopher J. Rabbat, Xin Chen
  • Razor Handle
    Publication number: 20120279039
    Abstract: A razor handle includes an at least partially hollow elongated structure and an at least partially hollow sleeve. The elongated structure has an interior surface and an exterior surface, a first opening at a proximate end, and a second opening along a length of the elongated structure. The sleeve has an interior surface and an exterior surface with a protrusion. The protrusion is adapted to extend through the second opening to the exterior surface of the elongated structure forming a gripping member.
    Type: Application
    Filed: July 17, 2012
    Publication date: November 8, 2012
    Inventors: Florina Winter, Chunfang Song, Dong Fang, RanMin Wang, Brian William Cataldo, Jing Jun Xia
  • GPR120 receptor agonists and uses thereof
    Patent number: 8299117
    Abstract: GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: October 30, 2012
    Assignee: Metabolex Inc.
    Inventors: Dong Fang Shi, Jiangao Song, Jingyuan Ma, Aaron Novack, Phuongly Pham, Imad Fayek Nashashibi, Christopher J. Rabbat, Xin Chen
  • HAND HELD DEVICE HAVING A ROTATIONAL AXIS
    Publication number: 20120260509
    Abstract: A hand held device comprising a handle, said handle comprising a grip portion and a connection portion, said connection portion rotating with respect to said grip portion about a rotational axis, said connection portion forming a docking portion suitable for receiving an optional head unit, said docking portion being positioned opposite distally away from said grip portion, wherein rotation of the connection portion relative to the grip portion generates a specific amount of dynamic torsional resistance. The handle has a set amount of stiffness and damping and/or stiffness and momentum of inertia such that the device provides a controlled return during rotation about the rotational axis so the device can contour about the surface in a desirable manner.
    Type: Application
    Filed: April 12, 2012
    Publication date: October 18, 2012
    Inventors: Dong Fang, Florina Winter, Ashok Bakul Patel, Rache Jane Otter, Matthias Richard Hien, Andrew Anthony Szczepanowski
  • Hand Held Device Having A Rotational Axis
    Publication number: 20120246947
    Abstract: A hand held device comprising: a handle, said handle comprising a grip portion and a connection portion, said connection portion rotating with respect to said grip portion about a rotational axis, said connection portion forming a docking portion suitable for receiving an optional head unit, said docking portion being positioned opposite distally away from said grip portion, wherein the grip portion and the connection portion are connected by a rod, said rod comprising a distal end non-rotatably attached to the grip portion and a proximal end non-rotatably attached to the connection portion, wherein rotational axis forms a central longitudinal axis of said rod.
    Type: Application
    Filed: March 28, 2012
    Publication date: October 4, 2012
    Inventors: DONG FANG, FLORINA WINTER
  • Bisaminoethanethiol-targeting ligand conjugates and compositions
    Patent number: 8236279
    Abstract: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: August 7, 2012
    Assignee: Board of Regents, The University of Texas System
    Inventors: David J. Yang, Chun W. Liu, Dong-Fang Yu, E. Edmund Kim
  • N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
    Patent number: 8183381
    Abstract: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control.
    Type: Grant
    Filed: July 10, 2008
    Date of Patent: May 22, 2012
    Assignee: Metabolex Inc.
    Inventors: Jingyuan Ma, Christopher J. Rabbat, Jiangao Song, Xin Chen, Imad Nashashibi, Zuchun Zhao, Aaron Novack, Dong Fang Shi, Peng Cheng, Yan Zhu, Alison Murphy
  • Cancer targets and uses thereof
    Patent number: 8168586
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: May 1, 2012
    Assignee: Celera Corporation
    Inventors: Dong Fang, Paul Moore, Steve Ruben, Sudeepta Aggarwal
  • GPR120 RECEPTOR AGONISTS AND USES THEREOF
    Publication number: 20110313003
    Abstract: GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
    Type: Application
    Filed: June 16, 2010
    Publication date: December 22, 2011
    Inventors: Dong Fang Shi, Jiangao Song, Jingyuan Ma, Aaron Novack, Phuongly Pham, Imad Fayek Nashashibi, Christopher J. Rabbat, Xin Chen
  • METHOD OF UTILIZING THE PTS GENE AND RNA INTERFERENCE OF THE ADS GENE TO INCREASE PATCHOULI ALCOHOL CONTENT IN ARTEMISIA ANNUA L.
    Publication number: 20110300546
    Abstract: The invention relates to a method of utilizing the pts gene and RNA interference of the ads gene to increase patchouli alcohol content in Artemisia annua L. plants. Using transgenic Artemisia annua L. plants, the method of the invention consistently increases the patchouli alcohol content in those plants, thus laying down a solid foundation for large-scale production of patchouli alcohol and other secondary metabolites such as terpenes other than artemisinin.
    Type: Application
    Filed: June 3, 2011
    Publication date: December 8, 2011
    Inventors: Ke Xuan Tang, Yue Yue Wang, Yue Li Tang, Dong-Fang Chen
  • METHOD OF UTILIZING THE PTS GENE AND ANTI-SENSE ADS TO INCREASE PATCHOULI ALCOHOL CONTENT IN ARTEMISIA ANNUA L.
    Publication number: 20110300547
    Abstract: The invention relates to a method of utilizing the pts gene and antisense ads to increase patchouli alcohol content in Artemisia annua L. plants. Using transgenic Artemisia annua L. plants, the method of the invention consistently increases the patchouli alcohol content in those plants, thus laying down a solid foundation for large-scale production of patchouli alcohol and other secondary metabolites such as terpenes other than artemisinin.
    Type: Application
    Filed: June 3, 2011
    Publication date: December 8, 2011
    Inventors: Ke Xuan Tang, Yue Yue Wang, Yue Li Tang, Dong-Fang Chen
  • GLYCOPEPTIDE COMPOSITIONS
    Publication number: 20110087003
    Abstract: The invention include glycopeptides having a glycoside and a peptide covalently bound through an amide bond. The glycopeptides may also include a diagnostic or therapeutic agent bound to the glycopeptide. A metal, such as a radionuclide, may also be chelated to the glycopeptide. Specific embodiments of the invention relate to glycopeptides made of chitosan covalently bound to a poly(amino acid) such as poly(glutamic acid) or poly(aspartic acid). Diagnostic agents conjugated to the glycopeptide may facilitate imaging. Specific therapeutic agents that may be conjugated to the glycopeptide include anticancer drugs, rheumatoid arthritis drugs, anticoagulants, anti-angiogenesis drugs, apoptosis drugs, osteoporosis drugs, steroids, and anti-inflammatory drugs. Some agents, such as radionuclides, may have both diagnostic and therapeutic effects.
    Type: Application
    Filed: December 16, 2010
    Publication date: April 14, 2011
    Inventors: I-Chien Wei, David J. Yang, Dong-Fang Yu
  • Mechanism-Based Targeted Pancreatic Beta Cell Imaging and Therapy
    Publication number: 20100278731
    Abstract: Compositions for imaging pancreatic beta cells comprise chelator-antidiabetic agent conjugates and optionally chelated metals.
    Type: Application
    Filed: November 2, 2009
    Publication date: November 4, 2010
    Inventors: David J. Yang, Chang-Sok Oh, Saady Kohanim, Dong-Fang Yu, Ali Azhdarinia, Jerry Bryant
  • ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF
    Publication number: 20100216827
    Abstract: Aryl GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
    Type: Application
    Filed: October 20, 2009
    Publication date: August 26, 2010
    Inventors: Jingyuan Ma, Aaron Novack, Imad Nashashibi, Phuongly Pham, Christopher J. Rabbat, Jiangao Song, Dong Fang Shi, Zuchun Zhao, Yun-Jung Choi, Xin Chen
  • GPR120 RECEPTOR AGONISTS AND USES THEREOF
    Publication number: 20100190831
    Abstract: GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
    Type: Application
    Filed: December 17, 2009
    Publication date: July 29, 2010
    Inventors: Dong Fang Shi, Jiangao Song, Jingyuan Ma, Aaron Novack, Phuongly Pham, Imad Fayek Nashashibi, Christopher J. Rabbat, Xin Chen
  • BISAMINOETHANETHIOL-TARGETING LIGAND CONJUGATES AND COMPOSITIONS
    Publication number: 20100055035
    Abstract: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.
    Type: Application
    Filed: September 21, 2009
    Publication date: March 4, 2010
    Inventors: David J. Yang, Chun W. Liu, Dong-Fang Yu, E. Edmund Kim